193 related articles for article (PubMed ID: 30001928)
21. Novel serology testing for sporadic inclusion body myositis: disease-specificity and diagnostic utility.
Herbert MK; Pruijn GJ
Curr Opin Rheumatol; 2015 Nov; 27(6):595-600. PubMed ID: 26285103
[TBL] [Abstract][Full Text] [Related]
22. Biomarkers of inclusion body myositis.
Greenberg SA
Curr Opin Rheumatol; 2013 Nov; 25(6):753-62. PubMed ID: 24067380
[TBL] [Abstract][Full Text] [Related]
23. Cytosolic 5'-Nucleotidase 1A As a Target of Circulating Autoantibodies in Autoimmune Diseases.
Lloyd TE; Christopher-Stine L; Pinal-Fernandez I; Tiniakou E; Petri M; Baer A; Danoff SK; Pak K; Casciola-Rosen LA; Mammen AL
Arthritis Care Res (Hoboken); 2016 Jan; 68(1):66-71. PubMed ID: 25892010
[TBL] [Abstract][Full Text] [Related]
24. Inclusion-body myositis and primary Sjögren syndrome: mechanisms for shared etiologies.
Limaye VS; Cash K; Smith C; Koszyca B; Patel S; Greenberg SA; Hissaria P
Muscle Nerve; 2020 May; 61(5):570-574. PubMed ID: 32035011
[TBL] [Abstract][Full Text] [Related]
25. Anti-Cytosolic 5'-Nucleotidase 1A in the Diagnosis of Patients with Suspected Idiopathic Inflammatory Myopathies: An Italian Real-Life, Single-Centre Retrospective Study.
Porcelli B; d'Alessandro M; Gupta L; Grazzini S; Volpi N; Bacarelli MR; Ginanneschi F; Biasi G; Bellisai F; Fabbroni M; Bennett D; Fabiani C; Cantarini L; Bargagli E; Frediani B; Conticini E
Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509600
[TBL] [Abstract][Full Text] [Related]
26. Anti-cytosolic 5'-nucleotidase 1A (cN1A) autoantibodies in motor neuron diseases.
Liewluck T
Neurology; 2017 Nov; 89(19):2017-2018. PubMed ID: 28954884
[No Abstract] [Full Text] [Related]
27. Inclusion body myositis: advancements in diagnosis, pathomechanisms, and treatment.
Schmidt K; Schmidt J
Curr Opin Rheumatol; 2017 Nov; 29(6):632-638. PubMed ID: 28832349
[TBL] [Abstract][Full Text] [Related]
28. Sporadic inclusion body myositis: new insights and potential therapy.
Machado PM; Dimachkie MM; Barohn RJ
Curr Opin Neurol; 2014 Oct; 27(5):591-8. PubMed ID: 25159931
[TBL] [Abstract][Full Text] [Related]
29. Inclusion Body Myositis.
Goyal NA
Continuum (Minneap Minn); 2022 Dec; 28(6):1663-1677. PubMed ID: 36537974
[TBL] [Abstract][Full Text] [Related]
30. [Sporadic Inclusion Body Myositis].
Yamashita S
Brain Nerve; 2023 Jul; 75(7):869-874. PubMed ID: 37431078
[TBL] [Abstract][Full Text] [Related]
31. [Recent progress in diagnosis and pathomechanism of inclusion body myositis].
Aoki M; Suzuki N; Kato M; Warita H
Rinsho Shinkeigaku; 2014; 54(12):1115-8. PubMed ID: 25672724
[TBL] [Abstract][Full Text] [Related]
32. Update in inclusion body myositis.
Machado P; Brady S; Hanna MG
Curr Opin Rheumatol; 2013 Nov; 25(6):763-71. PubMed ID: 24067381
[TBL] [Abstract][Full Text] [Related]
33. Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis.
Yeker RM; Pinal-Fernandez I; Kishi T; Pak K; Targoff IN; Miller FW; Rider LG; Mammen AL;
Ann Rheum Dis; 2018 May; 77(5):714-719. PubMed ID: 29363513
[TBL] [Abstract][Full Text] [Related]
34. Sporadic inclusion body myositis: A review of recent clinical advances and current approaches to diagnosis and treatment.
Needham M; Mastaglia FL
Clin Neurophysiol; 2016 Mar; 127(3):1764-73. PubMed ID: 26778717
[TBL] [Abstract][Full Text] [Related]
35. Seropositivity for NT5c1A antibody in sporadic inclusion body myositis predicts more severe motor, bulbar and respiratory involvement.
Goyal NA; Cash TM; Alam U; Enam S; Tierney P; Araujo N; Mozaffar FH; Pestronk A; Mozaffar T
J Neurol Neurosurg Psychiatry; 2016 Apr; 87(4):373-8. PubMed ID: 25857661
[TBL] [Abstract][Full Text] [Related]
36. Inclusion body myositis: a review of clinical and genetic aspects, diagnostic criteria and therapeutic approaches.
Mastaglia FL; Needham M
J Clin Neurosci; 2015 Jan; 22(1):6-13. PubMed ID: 25510538
[TBL] [Abstract][Full Text] [Related]
37. Development and evaluation of a standardized ELISA for the determination of autoantibodies against cN-1A (Mup44, NT5C1A) in sporadic inclusion body myositis.
Kramp SL; Karayev D; Shen G; Metzger AL; Morris RI; Karayev E; Lam Y; Kazdan RM; Pruijn GJ; Saschenbrecker S; Dähnrich C; Schlumberger W
Auto Immun Highlights; 2016 Dec; 7(1):16. PubMed ID: 27858337
[TBL] [Abstract][Full Text] [Related]
38. Inclusion Body Myositis and Neoplasia: A Narrative Review.
Damian L; Login CC; Solomon C; Belizna C; Encica S; Urian L; Jurcut C; Stancu B; Vulturar R
Int J Mol Sci; 2022 Jul; 23(13):. PubMed ID: 35806366
[TBL] [Abstract][Full Text] [Related]
39. Advances in serological diagnostics of inflammatory myopathies.
Benveniste O; Stenzel W; Allenbach Y
Curr Opin Neurol; 2016 Oct; 29(5):662-73. PubMed ID: 27538058
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of anti-NT5C1A antibodies in Japanese patients with autoimmune rheumatic diseases in comparison with other patient cohorts.
Muro Y; Nakanishi H; Katsuno M; Kono M; Akiyama M
Clin Chim Acta; 2017 Sep; 472():1-4. PubMed ID: 28687351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
